Ultimovacs ASA (ULTI) - Total Assets
Based on the latest financial reports, Ultimovacs ASA (ULTI) holds total assets worth Nkr115.86 Million NOK (≈ $12.19 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ultimovacs ASA - Total Assets Trend (2016–2024)
This chart illustrates how Ultimovacs ASA's total assets have evolved over time, based on quarterly financial data. Also see Ultimovacs ASA (ULTI) market capitalisation for the company's overall valuation and market capitalisation.
Ultimovacs ASA - Asset Composition Analysis
Current Asset Composition (December 2024)
Ultimovacs ASA's total assets of Nkr115.86 Million consist of 98.3% current assets and 1.7% non-current assets. Review total liabilities of Ultimovacs ASA to assess the company's total debt and financial obligations.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 92.7% |
| Accounts Receivable | Nkr0.00 | 0.0% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr0.00 | 0.0% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Ultimovacs ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ULTI share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ultimovacs ASA's current assets represent 98.3% of total assets in 2024, an increase from 94.6% in 2016.
- Cash Position: Cash and equivalents constituted 92.7% of total assets in 2024, up from 87.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Ultimovacs ASA Competitors by Total Assets
Key competitors of Ultimovacs ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Ultimovacs ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.62 | 4.85 | 19.29 |
| Quick Ratio | 3.62 | 4.85 | 19.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Nkr82.36 Million | Nkr216.01 Million | Nkr357.77 Million |
Ultimovacs ASA - Advanced Valuation Insights
This section examines the relationship between Ultimovacs ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.52 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | -66.8% |
| Total Assets | Nkr115.86 Million |
| Market Capitalization | $52.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ultimovacs ASA's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Ultimovacs ASA's assets decreased by 66.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ultimovacs ASA (2016–2024)
The table below shows the annual total assets of Ultimovacs ASA from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr115.86 Million ≈ $12.19 Million |
-66.81% |
| 2023-12-31 | Nkr349.04 Million ≈ $36.73 Million |
-31.52% |
| 2022-12-31 | Nkr509.67 Million ≈ $53.63 Million |
-22.25% |
| 2021-12-31 | Nkr655.54 Million ≈ $68.98 Million |
+23.75% |
| 2020-12-31 | Nkr529.72 Million ≈ $55.74 Million |
+10.81% |
| 2019-12-31 | Nkr478.04 Million ≈ $50.30 Million |
+151.79% |
| 2018-12-31 | Nkr189.86 Million ≈ $19.98 Million |
+6.17% |
| 2017-12-31 | Nkr178.82 Million ≈ $18.82 Million |
+116.42% |
| 2016-12-31 | Nkr82.63 Million ≈ $8.69 Million |
-- |
About Ultimovacs ASA
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.